ENZN » Topics » Base Salary

This excerpt taken from the ENZN DEF 14A filed Apr 13, 2009.

          Base Salary

          The Compensation Committee aims to set base salaries at levels that are competitive with those paid to senior executives at companies included in the Compensation Peer Group. The Compensation Committee believes that this will allow the Company to attract and retain the executive talent required to lead the Company, since we compete with a large number of companies in the biopharmaceutical industry, including large pharmaceutical companies, for executive talent. Salaries are reviewed annually and in connection with promotions. The Compensation Peer Group is considered in making salary determinations to align our pay practices with other companies in the pharmaceutical and biotechnology industries. Individual job performance is also considered in setting salaries. Our Chief Executive Officer conducts performance reviews of members of executive management and makes recommendations to the Compensation Committee on salary, including salary increases, based on his judgment of the individual’s performance, using the following criteria for evaluation: attainment of job accountabilities and functional goals, leadership qualities, strategic contribution and adoption of the Company’s corporate values that focus on five key operating principles – people, passion, performance, pride, and a steadfast commitment to delivering on promises. The Compensation Committee reviews these recommendations independently and approves the annual salary and salary increases, with any modifications it considers appropriate based on its own interaction with executive management and review of accomplishments. See the discussion in the Corporate Governance section above regarding the Compensation Committee for additional disclosure concerning our Chief Executive Officer’s role in compensation decisions.

          The Compensation Committee reviewed base salaries at the end of the fiscal year ended December 31, 2008 and determined not to increase any executive officer salaries for 2009. This determination was based on Compensation Peer Group market data reviewed by Mercer and the determination that current base salary levels remained competitive. For additional information regarding the base salaries in fiscal year 2008, see the Summary Compensation Table below. The base salaries effective January 1, 2009 are as set forth below.

13


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Name and Title of Executive Officer

 

2008 Base Salary

 

Salary Increase (%)

 

Base Salary effective
January 1, 2009

 


 


 


 



Jeffrey H. Buchalter, Chairman of the Board, President and Chief Executive Officer

 

 

$

855,000

 

 

 

$

0

 (0%)

 

 

$

855,000

 

 

Craig A. Tooman, Executive Vice President, Finance and Chief Financial Officer

 

 

$

505,000

 

 

 

$

0

 (0%)

 

 

$

505,000

 

 

Ivan D. Horak, M.D., Executive Vice President, Research and Development
and Chief Scientific Officer

 

 

$

533,663

 

 

 

$

0

 (0%)

 

 

$

533,663

 

 

Ralph del Campo, Executive Vice President, Technical Operations

 

 

$

412,886

 

 

 

$

0

 (0%)

 

 

$

412,886

 

 

Paul S. Davit, Executive Vice President, Human Resources

 

 

$

349,830

 

 

 

$

0

 (0%)

 

 

$

349,830

 

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki